HK Movers | Hengrui Pharma Stock Jumps 4% to New High After Gaining Approval for Clinical Trial of New Inhalation Drug

Reuters

07/10

Hengrui Pharma stock gained another 4% to new high as it has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received a "Drug Clinical Trial Approval Notification" for HRS-9821 inhalation powder.

This approval marks a significant milestone in the drug's development process, allowing it to proceed to clinical trials in accordance with the regulations of the People's Republic of China.

The company emphasizes the lengthy and complex journey from development to market, acknowledging the uncertainties that may impact medicinal product R&D and marketing. Jiangsu Hengrui remains committed to advancing this R&D project and will continue to provide updates on its progress as required by national stipulations.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550965678"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550965678\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550965678?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-10 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550965678","market":"hk","top_or_hot":-1,"title":"HK Movers | Hengrui Pharma Stock Jumps 4% to New High After Gaining Approval for Clinical Trial of New Inhalation Drug","media":"Reuters","content":"<html><head></head><body><p>Hengrui Pharma stock gained another 4% to new high as it has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received a &#34;Drug Clinical Trial Approval Notification&#34; for HRS-9821 inhalation powder.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b43f144e20c6dd6e2fa007a7cd1aee1f\" tg-width=\"912\" tg-height=\"618\"/></p><p>This approval marks a significant milestone in the drug&#39;s development process, allowing it to proceed to clinical trials in accordance with the regulations of the People&#39;s Republic of China.</p><p>The company emphasizes the lengthy and complex journey from development to market, acknowledging the uncertainties that may impact medicinal product R&amp;D and marketing. Jiangsu Hengrui remains committed to advancing this R&amp;D project and will continue to provide updates on its progress as required by national stipulations.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Movers | Hengrui Pharma Stock Jumps 4% to New High After Gaining Approval for Clinical Trial of New Inhalation Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Movers | Hengrui Pharma Stock Jumps 4% to New High After Gaining Approval for Clinical Trial of New Inhalation Drug\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-10 10:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><head></head><body><p>Hengrui Pharma stock gained another 4% to new high as it has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received a &#34;Drug Clinical Trial Approval Notification&#34; for HRS-9821 inhalation powder.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b43f144e20c6dd6e2fa007a7cd1aee1f\" tg-width=\"912\" tg-height=\"618\"/></p><p>This approval marks a significant milestone in the drug&#39;s development process, allowing it to proceed to clinical trials in accordance with the regulations of the People&#39;s Republic of China.</p><p>The company emphasizes the lengthy and complex journey from development to market, acknowledging the uncertainties that may impact medicinal product R&amp;D and marketing. Jiangsu Hengrui remains committed to advancing this R&amp;D project and will continue to provide updates on its progress as required by national stipulations.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"證金概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL4KgXdb:1","article_id":"2550965678","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550965678","pubTimestamp":1752113660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hengrui Pharma stock gained another 4% to new high as it has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received a \"Drug Clinical Trial Approval Notification\" for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0012":"证金概念","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","01276":"恒瑞医药","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0028":"国家队","BK0183":"MSCI概念","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","BK0060":"抗癌","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0196":"行业龙头","BK0239":"医药制造","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0188":"融资融券"},"translate_title":"恒瑞医药吸入新药临床试验获批后股价上涨4%创新高","themeId":"d3f7ddccdb763b8bb4f259a3025424e6","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":0.9},"content_text":"Hengrui Pharma stock gained another 4% to new high as it has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received a \"Drug Clinical Trial Approval Notification\" for HRS-9821 inhalation powder.This approval marks a significant milestone in the drug's development process, allowing it to proceed to clinical trials in accordance with the regulations of the People's Republic of China.The company emphasizes the lengthy and complex journey from development to market, acknowledging the uncertainties that may impact medicinal product R&D and marketing. Jiangsu Hengrui remains committed to advancing this R&D project and will continue to provide updates on its progress as required by national stipulations.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}